期刊文献+

缺氧性肺动脉高压发病机制及靶向治疗研究 被引量:3

下载PDF
导出
摘要 缺氧性肺动脉高压(hypoxia pulmonary hypertension,HPH)是慢性肺源性心脏病及慢性高原病等临床疾病发病的重要病理生理变化之一,是由于长期慢性缺氧导致的,其主要特征为低氧性肺动脉收缩增强,肺小动脉中层平滑肌异常增生,肺血管重构,最终导致右心室肥大及右心衰竭[1].WHO对肺高压的分型中,将“伴发肺脏疾病和/或低氧血症的肺高血压”归纳为第Ⅲ型,包括慢性阻塞性肺疾病(chronic obstructive pulmonary disease,COPD)间质性肺疾病(结缔组织疾病,硬皮病),睡眠呼吸障碍,慢性高原病,肺泡低通气综合征及肺泡毛细血管发育不良[2].
出处 《老年医学与保健》 CAS 2014年第3期138-142,共5页 Geriatrics & Health Care
基金 基金项目:湖北省卫生厅项目(1301-1412)
  • 相关文献

参考文献26

  • 1Tuder RM, Stacher E, Robinson J, etal. Pathology of pulmonary hypertension [J]. ClinChestMed, 2013, 34 (4): 639-650.
  • 2Poor HD, Girgis R, Studer SM. World Health Organization Group Ⅲ pulmonary hypertension [J]. Prog Cardiovasc Dis, 2012, 55 (2): 119-127.
  • 3E1 Chami H, Hassoun PM. Immune and inflammatory mech- anisms in pulmonary arterial hypertension [J]. Prog Cardiovasc Dis, 2012, 55 (2): 218-228.
  • 4Eltzschig HK, Carmeliet P. Hypoxia and inflammation [J]. N EnglJMed, 2011, 364 (7): 656-665.
  • 5Price LC, Wort SJ, Perros F, etaL Inflammation in pulmonary arterial hypertension [J]. Chest, 2012, 141 (1): 210-221.
  • 6Remillard CV, Yuan JX. TRP channels, CCE, and the pulmonary vascular smooth muscle [J]. Microcirculation, 2006, 13 (8): 671-692.
  • 7Ward JP, Robertson TP, Aaronson PI. Capacitative calcium entry: a central role in hypoxic pulmonary vasoconstriction? [J]. Am J Physiol Lung Cell Mol Physiol, 2005, 289 (1): L2-L4.
  • 8Wang J, Weigand L, Lu W, et al. Hypoxia inducible factor 1 mediates hypoxia-induced TRPC expression and elevated intrac- ellular Ca2 + in pulmonary arterial smooth muscle cells [J]. Circ Res, 2006, 98 (12): 1528-1537.
  • 9Bonnet S, Rochefort G, Sutendra G, et al. The nuclear factor of activated T ceils in pulmonary arterial hypertension can be therapeutically targeted [J]. Proc Natl Acad Sci USA, 2007, 104 (27): 11418-11423.
  • 10de Frutos S, Diaz JM, Nitta CH, etal. Endothelin-1 contributes to increased NFATc3 activation by chronic hypoxia in pulmon- aryarteries [J]. AmJPhysiolCellPhysiol, 2011, 301 (2): C441-C450.

同被引文献44

  • 1Harsha V. Ganga,Sanjeev U. Nair,Venkata K. Puppala,Wayne L. Miller.Risk of New-Onset Atrial Fibrillation in Elderly Patients with the Overlap Syndrome: A Retrospective Cohort Study[J].Journal of Geriatric Cardiology,2013,10(2):129-134. 被引量:10
  • 2荆志成.2010年中国肺高血压诊治指南[J].中国医学前沿杂志(电子版),2011,3(2):62-81. 被引量:118
  • 3Adir Y, Harari S. Pulmonary hypertension associated with chronic obstructive lung disease and idiopathic pulmonary fibrosis[J]. Curt Opin Pulm Med,2014,20(5):414-420.
  • 4Doggrell SA,Rho-kinase inhibitors show promise in pulmonary hypertension[J]. Expert Opin Investig Drugs, 2005,14(9):1157- 1159.
  • 5Hassoun PM, Mouthon L, Barbera JA, et al. Inflammation, growth factors, and pulmonary vascular remodeling[J]. J Am Coil Cardiol, 2009,54( 1 ):S10-19.
  • 6Fagan KA, Oka M, Bauer NR, et al. Attenuation of acute hypoxic pulmonary vasoconstriction and hypoxic pulmonary hypertension in mice by inhibition of Rho-kinase [J]. Am J Physiol Lung Cell Mol Physiol, 2004, 287(4):L656-664.
  • 7Prorovle J, Gorovoy M, Niu J, et al. A novel mechanism of G protein-dependent phosphorylation of phosphoprotein[J]. J Biol Chem,2005,280(38):32866-32876.
  • 8Guilluy C, Sanzeau V, Rolli-Derkinderen M, et al. Inhibition of RhoA/Rho kinase pathway is involved in the beneficial effect of sildenafil on pulmonary hypertension[J]. Br J Pharmacol, 2005, 146(7):1010-1018.
  • 9Yasuda T, Tada Y, Tanabo N, et al. Rho-kinase inhibition alleviates pulmonary hypertension in transgenie mice expressing a dominant-negative type II bone morpbogenetie protein receptor gene[J]. Am J Physiol Lung Cell Mol Physial, 2011, 301(5):L667-674.
  • 10lshikura K, Yamada N, Ito M, et al. Beneficial acute effects of rho-kinase inhibitor in patients with pulmonary arterial hypertension[J]. Circ J, 2006,70(2):174-178.

引证文献3

二级引证文献7

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部